Engineered immune cells take on rare Muscle-Weakening disease

This early-phase study tests a new treatment called SENL103 for people with refractory generalized myasthenia gravis, a condition that causes severe muscle weakness. The treatment uses the patient's own immune cells, modified to target and destroy harmful cells that attack the muscles. The main goals are to check safety and see if it can improve daily activities like talking, swallowing, and walking. Only 6 to 24 adults with hard-to-treat disease will take part.